OxySure (OXYS) Announces CE Mark Approval for OxySure Model 615 Portable Emergency Oxygen Device
Frisco, Texas, USA, April 2, 2014 – OxySure Systems, Inc. (OXYS: OTCQB) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology is pleased to announce its OxySure Model 615 portable emergency oxygen device has received CE Mark approval, a critical step toward launching this unique product into the thirty countries belonging to the European Economic Area (EEA).
The OxySure Model 615 enables lay persons, from bystanders to family members, to administer medical oxygen easily and quickly in any medical emergency, while waiting for paramedics or first responders to arrive on the scene.
“We are excited to introduce our innovative, lifesaving product to the European market,” said Julian T. Ross, CEO of OxySure. “Our product can now bear the CE Mark, which demonstrates that the OxySure Model 615 complies with stringent requirements related to the quality, safety, and performance of medical oxygen devices found in the applicable EU laws.”
Model 615 has already been used in connection with thousands of saves in the US alone including cardiac arrest, asthma attacks, sickle cell disease issues, COPD exacerbations, allergy attacks, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning and diabetic emergencies. Like the US, European first responders typically provide supplemental oxygen to patients immediately upon arrival. OxySure’s Model 615 allows lay rescuers to begin oxygen delivery sooner, bridging the gap until professional responders arrive on the scene. For more information about the OxySure Model 615, please visit http://www.oxysure.com/aed/index.php/new-model.
OxySure is also announcing plans to work on imminent product launches with distribution partners already appointed. The Company plans to appoint new distributors in the coming months in European countries where the Company does not currently have representation. The European Economic Area (EEA) comprises the three member states of the European Free Trade Association (EFTA) (Iceland, Liechtenstein and Norway), and the 27 member states of the European Union (EU), including Germany, France, Italy, Spain and Portugal.
About OxySure Systems, Inc.
OxySure Systems, Inc. (OTCQB : OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” (IDLH) environments. www.OxySure.com
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.
Stonegate Securities, Inc.
214-987-4121 / 972-294-6461